HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsGaëlle Thomas(Université de Montpellier), Christel Larbouret(Inserm)OncotargetJuly 17, 201410.18632/oncotarget.2231Cited by 44SaveCiteExport RISWatch citationsRelated Papers<i>In vivo</i> Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas|Clinical Cancer Research|2007|84Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts|Annals of Oncology|2009|49